FGFR3 and breast cancer: In addition to inhibiting ligand binding, the specific FGFR3 monoclonal antibody (R3mAb) created by Qing et al. also blocks the dimerization of wild-type and different mutant FGFR3, which prevents the growth of BC RT112 and RT4 cell lines and prevents phosphorylation of FGFR3 and p42/44 MAPK [100].